<DOC>
	<DOC>NCT00135343</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of a novel nucleoside sparing regimen containing atazanavir, ritonavir and efavirenz, using two different doses of atazanavir.</brief_summary>
	<brief_title>A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Provide written informed consent HIV positive with plasma HIV RNA viral load of ≥ 1000 copies/mL and CD4 cell count of ≥ 50 cells/mm3 Antiretroviral (ARV) naive prior to enrollment Normal plasma triglycerides ≤ 200 mg/dL Women of childbearing age must use effective barrier contraception Pregnancy or breast feeding Evidence of resistance to antiretroviral drugs History of elevated blood cholesterol or triglycerides History of diabetes Hypersensitivity to any component of the study drugs Any cholesterol or triglyceride lowering medications in the past six months Use of growth hormone, megestrol acetate, or anabolic steroids in the past six months Imprisonment or involuntary incarceration for medical treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>HIV/AIDS</keyword>
</DOC>